  | Ancion, M., Luyckx, M., Renard, M., Reynders, C., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., RONCARATI, P., Herfs, M., & Hubert, P. (12 June 2023). Approach using "second generation" immune checkpoint inhibitors for the treatment of triple-negative breast cancer [Poster presentation]. EACR 2023, Turin, Italy. |
 | Bruyere, D., RONCARATI, P., Lebeau, A., Lerho, T., Poulain, F., Hendrick, E., Pilard, C., Reynders, C., Ancion, M., Luyckx, M., Renard, M., Jacob, Y., Twizere, J.-C., Peiffer, R., Peulen, O., Delvenne, P., Hubert, P., McBride, A., Gillet, N., ... Herfs, M. (2023). Human papillomavirus E6/E7 oncoproteins promote radiotherapy-mediated tumor suppression by globally hijacking host DNA damage repair. Theranostics, 13 (3), 1130 - 1149. doi:10.7150/thno.78091  Peer Reviewed verified by ORBi |
 | Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Bruyère, D., Hendrick, E., Delvenne, P., Hubert, P., & Herfs, M. (09 September 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV in carcinogenesis [Poster presentation]. INTERUNIVERSITY PHD STUDENT DAY. |
 | Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Hendrick, E., Bruyère, D., Delvenne, P., Hubert, P., & Herfs, M. (06 September 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV infections in carcinogenesis [Poster presentation]. GIGA-Day 2022. |
Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., Delvenne, P., Hubert, P., & Herfs, M. (29 April 2022). Histopathological characterization of esophageal tumors and potential involvement of high-risk HPV in carcinogenesis [Paper presentation]. Séminaire du GIGA-Cancer, Belgium. |
 | Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Hendrick, E., Bruyère, D., Pilard, C., Delvenne, P., Hubert, P., & Herfs, M. (08 April 2022). Histopathological characterization of esophageal cancers and potential role of high-risk HPV infections [Poster presentation]. Séminaire des chercheurs Télévie 2022, Belgium. |
 | Lebeau, A.* , Bruyère, D.* , RONCARATI, P., Peixoto, P., Hervouet, E., COBRAIVILLE, G., Taminiau, B., Masson, M., Gallego, C., Mazzucchelli, G., Smargiasso, N., Fleron, M., Baiwir, D., Hendrick, E., Pilard, C., Lerho, T., Reynders, C., Ancion, M., GREIMERS, R., ... Herfs, M. (28 February 2022). HPV infection alters vaginal microbiome through down-regulating host mucosal innate peptides used by Lactobacilli as amino acid sources. Nature Communications, 13 (1), 1076. doi:10.1038/s41467-022-28724-8 Peer Reviewed verified by ORBi* These authors have contributed equally to this work. |
 | Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Pilard, C., Bruyère, D., Hendrick, E., Delvenne, P., Hubert, P., & Herfs, M. (14 December 2021). Histopathological characterization of esophageal cancers and potential role of high-risk HPV infections [Poster presentation]. Giga Cancer Day 2021. |
 | Reynders, C., RONCARATI, P., Ancion, M., Lerho, T., Bruyère, D., Hendrick, E., Pilard, C., Hubert, P., Delvenne, P., & Herfs, M. (01 October 2021). Caractérisation histopathologique des cancers œsophagiens et potentiel rôle des HPV [Paper presentation]. Conférence annuelle de l'Association Francophone pour l'étude des Infections à Papillomavirus et Polyomavirus, France. |
  | Bruyère, D., Monnien, F., Colpart, P., RONCARATI, P., Vuitton, L., Hendrick, E., Lepinoy, A., Luquain, A., Pilard, C., Lerho, T., Molimard, C., Maingon, P., Arnould, L., Bone-Lepinoy, M.-C., Dusserre, L., Martin, L., Reynders, C., Ancion, M., Peiffert, D., ... Herfs, M. (2021). Treatment algorithm and prognostic factors for patients with stage I–III carcinoma of the anal canal: a 20-year multicenter study. Modern Pathology, 34, 116-130. doi:10.1038/s41379-020-0637-6 Peer Reviewed verified by ORBi |
 | Hubert, P., RONCARATI, P., Demoulin, S., Pilard, C., Ancion, M., Reynders, C., Lerho, T., Bruyère, D., Lebeau, A., Radermecker, C., Meunier, M., Nokin, M.-J., Hendrick, E., Peulen, O., Delvenne, P., & Herfs, M. (2021). Extracellular HMGB1 blockade inhibits tumor growth through profoundly remodeling immune microenvironment and enhances checkpoint inhibitor-based immunotherapy. Journal for ImmunoTherapy of Cancer, 9 ((3)), 001966. doi:10.1136/jitc-2020-001966 Peer Reviewed verified by ORBi |
Pilard, C., RONCARATI, P., Hendrick, E., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (03 November 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Paper presentation]. Cytokines 2020, Seattle (Virtual), United States. |
Pilard, C., RONCARATI, P., Hendrick, E., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (03 October 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. 7th Immunotherapy of Cancer Conference (ITOC7), Munich (Virtual), Germany. |
 | Pilard, C., RONCARATI, P., Hendrick, E., Lebeau, A., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (01 October 2020). P08.03 Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy. Journal for ImmunoTherapy of Cancer, 8 (Suppl 2), 50-A51. doi:10.1136/jitc-2020-ITOC7.99 |
 | Pilard, C., RONCARATI, P., Hendrick, E., Lebeau, A., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (07 February 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. BACR 2020, Jette, Belgium. |
 | Pilard, C., RONCARATI, P., Hendrick, E., Lebeau, A., Bruyère, D., Lerho, T., Ancion, M., Reynders, C., DELVENNE, P., Herfs, M., & Hubert, P. (29 January 2020). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. Télévie Seminar 2020, Bruxelles, Belgium. |
Hendrick, E. (29 January 2020). Involvement of Mucin Secretion in Cellular Vulnerability to HPV-related Carcinogenesis [Poster presentation]. Séminaire Télévie 2020. |
Hendrick, E. (29 January 2020). Involvement of Mucin Secretion in Cellular Vulnerability to HPV-related Carcinogenesis [Poster presentation]. Séminaire Télévie 2020, Bruxelles, Belgium. |
 | Lachat, C., Bruyère, D., Etcheverry, A., Aubry, M., Mosser, J., Warda, W., Herfs, M., Hendrick, E., Ferrand, C., Borg, C., Delage-Mourroux, R., Feugeas, J.-P., Guittaut, M., Hervouet, E., & Peixoto, P. (2020). EZH2 and KDM6B Expressions Are Associated with Specific Epigenetic Signatures during EMT in Non Small Cell Lung Carcinomas. Cancers, 12, 3649-3671. doi:10.3390/cancers12123649 Peer Reviewed verified by ORBi |
Hendrick, E. (03 October 2019). Involvement of Mucin Secretion in Cellular Vulnerability to HPV-related Carcinogenesis [Paper presentation]. AFIPP, Besançon, France. |
 | Pilard, C., RONCARATI, P., Lebeau, A., Bruyère, D., Hendrick, E., DELVENNE, P., Herfs, M., & Hubert, P. (21 May 2019). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. Immunology Day 2019, Liège, Belgium. |
 | Pilard, C., RONCARATI, P., Lebeau, A., Bruyère, D., Hendrick, E., DELVENNE, P., Herfs, M., & Hubert, P. (01 February 2019). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. BACR 2019, Anvers, Belgium. |
Hendrick, E. (28 January 2019). Involvement of Mucin Secretion in Cellular Vulnerability to HPV-related Carcinogenesis [Poster presentation]. Séminaire Télévie 2019. |
 | Pilard, C., RONCARATI, P., Lebeau, A., Bruyère, D., Hendrick, E., DELVENNE, P., Herfs, M., & Hubert, P. (28 January 2019). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. Télévie Seminar 2019, Gembloux, Belgium. |
 | Peixoto, P., Etcheverry, A., Aubry, M., Missey, A., Lachat, C., Perrard, J., Hendrick, E., Delage-Mourroux, R., Mosser, J., Borg, C., Feugeas, J.-P., Herfs, M., Boyer-Guittaut, M., & Hervouet, E. (2019). EMT is associated with an epigenetic signature of ECM remodeling genes. Cell Death and Disease, 10 (3), 205. doi:10.1038/s41419-019-1397-4 Peer Reviewed verified by ORBi |
Hendrick, E. (27 September 2018). Involvement of mucin secretion in cellular vulnerability to HPV-related carcinogenesis [Paper presentation]. Association Francophone pour l'Etude des Infections par les Papillomavirus et les Polyomavirus (AFIPP), Obernai, France. |
 | Pilard, C., RONCARATI, P., Lebeau, A., Bruyère, D., Hendrick, E., DELVENNE, P., Herfs, M., & Hubert, P. (13 September 2018). Combining PD-1/PD-L1 blockade and RANKL inhibitors to treat breast cancers unresponsive to standard therapy [Poster presentation]. GIGA-Cancer Day 2018, Liège, Belgium. |
 | Bruyère, D., Lebeau, A., RONCARATI, P., Hendrick, E., Masson, M., Twizere, J.-C., Pilard, C., Hubert, P., DELVENNE, P., & Herfs, M. (30 May 2018). Deciphering the radiosensitivity of HPV-positive tumors [Poster presentation]. 5th meeting on emerging issues in oncogenic virus research, San Pietro in Bevagna, Italy. |
 | Bruyère, D., Lebeau, A., RONCARATI, P., Hendrick, E., Masson, M., Twizere, J.-C., Pilard, C., Hubert, P., DELVENNE, P., & Herfs, M. (28 May 2018). Deciphering the radiosensitivity of HPV-positive tumors [Poster presentation]. EDT-Immunology day 2018, Liège, Belgium. |
Lebeau, A., Bruyère, D., Hendrick, E., Pilard, C., RONCARATI, P., TAZIAUX, S., Hubert, P., Delvenne, P., & Herfs, M. (28 May 2018). HPV-related innate peptide inhibition promotes the acquisition of bacterial/fungal infections within the genital tract [Poster presentation]. Immunology day 2018, Liège, Belgium. |
Lebeau, A., Bruyère, D., Hendrick, E., Pilard, C., RONCARATI, P., TAZIAUX, S., Hubert, P., Delvenne, P., & Herfs, M. (01 February 2018). HPV-related innate peptide inhibition promotes the acquisition of bacterial/fungal infections within the genital tract [Poster presentation]. Annual Televie seminar, Bruxelles, Belgium. |
 | Asgarova, A., Asgarov, K., Godet, Y., Peixoto, P., Nadaradjane, A., Boyer-Guittaut, M., Galaine, J., Guenat, D., Mougey, V., Perrard, J., Pallandre, J.-R., Bouard, A., Balland, J., Tirole, C., Adotevi, O., Hendrick, E., Herfs, M., Cartron, P.-F., Borg, C., & Hervouet, E. (2018). PD-L1 expression is regulated by both DNA methylation and NF-kB during EMT signaling in non-small cell lung carcinoma. Oncoimmunology, 7(5), 1423170. doi:10.1080/2162402X.2017.1423170 Peer Reviewed verified by ORBi |
 | Herfs, M., RONCARATI, P., KOOPMANSCH, B., Peulen, O., Bruyère, D., Lebeau, A., Hendrick, E., Hubert, P., PONCIN, A., Penny, W., Piazzon, N., Monnien, F., Guenat, D., Mougin, C., Prétet, J.-L., Vuitton, L., SEGERS, K., LAMBERT, F., BOURS, V., ... Delvenne, P. (2018). A dualistic model of primary anal canal adenocarcinoma with distinct cellular origins, etiologies, inflammatory microenvironments and mutational signatures: implications for personalized medicine. British Journal of Cancer, 118(10), 1302-1312. doi:10.1038/s41416-018-0049-2 Peer Reviewed verified by ORBi |
Hendrick, E. (2017). Nouvelles combinaisons thérapeutiques pour améliorer l'efficacité anti-tumorale de l'inhibition d'HDAC5 [Doctoral thesis, ULiège - Université de Liège]. ORBi-University of Liège. https://orbi.uliege.be/handle/2268/211419 |
 | Hendrick, E., Peixoto, P., Blomme, A., Polese, C., Matheus, N., Cimino, J., Frère, A., Mouithys-Mickalad, A., Serteyn, D., Bettendorff, L., Elmoualij, B., De Tullio, P., Eppe, G., Dequiedt, F., Castronovo, V., & Mottet, D. (2017). Metabolic inhibitors accentuate the anti-tumoral effect of HDAC5 inhibition. Oncogene. doi:10.1038/onc.2017.103 Peer Reviewed verified by ORBi |
 | Frère, A., Baroni, A., Hendrick, E., Delvigne, A. S., Orange, F., Peulen, O., Dakwar, G., Diricq, J., Dubois, P., Evrard, B., Remaut, K., Braeckmans, K., De Smedt, S., Laloy, J., Dogne, J. M., Feller, G., Mespouilles, L., Mottet, D., & Piel, G. (2017). PEGylated and Functionalized Aliphatic Polycarbonate Polyplex Nanoparticles for Intravenous Administration of HDAC5 siRNA in Cancer Therapy. ACS Applied Materials and Interfaces, 25 (9(3)), 2181-2195. doi:10.1021/acsami.6b15064 Peer Reviewed verified by ORBi |
Hendrick, E., Peixoto, P., Polese, C., Matheus, N., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Eppe, G., Castronovo, V., & Mottet, D. (03 December 2015). Compensatory Metabolism Promotes Cancer Cell Adaptation to HDAC5 Silencing [Poster presentation]. Séminaires des chercheurs Télévie 2016, Gembloux, Belgium. |
Hendrick, E. (December 2015). Compensatory Metabolism Promotes Cancer Cell Adaptation to HDAC5 Silencing [Paper presentation]. Séminaires des chercheurs Télévie 2016, Gembloux, Belgium. |
Hendrick, E. (19 November 2015). Compensatory Metabolism Promotes Cancer Cell Adaptation to HDAC5 Silencing [Paper presentation]. Séminaires Giga UTR, Liège, Belgium. |
Hendrick, E., Peixoto, P., Polese, C., Matheus, N., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Sonveaux, P., Castronovo, V., & Mottet, D. (11 February 2015). HDAC5 Depletion in Cancer Cells Induces an Oxidative Stress and Leads to a Metabolic Reprogramming toward Glucose and Glutamine Metabolism [Poster presentation]. Seminaires des chercheurs Télévie 2015, Bruxelles, Belgium. |
Hendrick, E., Peixoto, P., Polese, C., Matheus, N., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Sonveaux, P., Castronovo, V., & Mottet, D. (31 January 2015). HDAC5 Depletion in Cancer Cells Induces an Oxidative Stress and Leads to a Metabolic Reprogramming toward Glucose and Glutamine Metabolism [Poster presentation]. ABEC TUmor Metabolism and Mitochondria, Bruxelles, Belgium. |
Hendrick, E., Peixoto, P., Polese, C., Matheus, N., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Sonveaux, P., Castronovo, V., & Mottet, D. (27 January 2015). HDAC5 Depletion in Cancer Cells Induces an Oxidative Stress and Leads to a Metabolic Reprogramming toward Glucose and Glutamine Metabolism [Poster presentation]. Giga Cancer Day 2015 Current Advances in Medical Genetics and Genomics, Liège, Belgium. |
 | Frère, A., Kawalec, M., Tempelaar, S., Peixoto, P., Hendrick, E., Peulen, O., Evrard, B., Dubois, P., Mespouille, L., Mottet, D., & Piel, G. (2015). Impact of the Structure of Biocompatible Aliphatic Polycarbonates on siRNA Transfection Ability. Biomacromolecules. doi:10.1021/bm501676p Peer Reviewed verified by ORBi |
Hendrick, E. (2015). Compensatory Metabolism Promotes Cancer Cell Adaptation to HDAC5 Silencing [Paper presentation]. Séminaires des chercheurs Télévie 2016, Gembloux, Belgium. |
Hendrick, E., Peixoto, P., Polese, C., Matheus, N., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Sonveaux, P., Castronovo, V., & Mottet, D. (30 September 2014). HDAC5 Depletion in Cancer Cells Induces an Oxidative Stress and Leads to a Metabolic Reprogramming toward Glucose and Glutamine Metabolism [Paper presentation]. Annual Mini symposium 2014, Liège, Belgium. |
Hendrick, E., Peixoto, P., Polese, C., Matheus, N., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Sonveaux, P., Castronovo, V., & Mottet, D. (25 September 2014). HDAC5 Depletion in Cancer Cells Induces an Oxidative Stress and Leads to a Metabolic Reprogramming toward Glucose and Glutamine Metabolism [Poster presentation]. Metabolism and Cancer Nice, Nice, France. |
Hendrick, E., Peixoto, P., Polese, C., Matheus, N., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Sonveaux, P., Castronovo, V., & Mottet, D. (19 May 2014). Glucose-dependent metabolic reprogramming in HDAC5-depleted cancer cells [Poster presentation]. Giga Cancer Day 2014 THE LYMPHATIC SYSTEM : THE BED AND BENCH POINT OF VIEWS, Liège, Belgium. |
Hendrick, E. (25 April 2014). Glucose-dependent metabolic reprogramming in HDAC5-depleted cancer cells [Poster presentation]. Reactive Oxygen Species in Cell Metabolism 11th Meeting of the FRS-FNRS contact group on oxidative stress and anti-oxidants 210th Meeting of the Belgian Society of Biochemistry and Molecular Biology, Belgium. |
Hendrick, E., Peixoto, P., Polese, C., Matheus, N., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Sonveaux, P., Castronovo, V., & Mottet, D. (25 April 2014). Glucose-dependent metabolic reprogramming in HDAC5-depleted cancer cells [Poster presentation]. Reactive Oxygen Species in Cell Metabolism 11th Meeting of the FRS-FNRS contact group on oxidative stress and anti-oxidants 210th Meeting of the Belgian Society of Biochemistry and Molecular Biology, Belgium. |
Hendrick, E., Peixoto, P., Polese, C., Matheus, N., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Castronovo, V., & Mottet, D. (01 February 2014). Complex I Mitochondrial Dysfunction in HDAC5-depleted Cancer Cells Induces Glucose-dependent Metabolic Reprogramming [Poster presentation]. Association Belge pour l'étude du cancer A.B.E.C 2014, Anvers, Belgium. |
Hendrick, E., Peixoto, P., Matheus, N., Polese, C., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Sonveaux, P., Castronovo, V., & Mottet, D. (27 January 2014). Complex I Mitochondrial Dysfunction in HDAC5-depleted Cancer Cells Induces Glucose-dependent Metabolic Reprogramming [Poster presentation]. Giga Day 2014, Liège, Belgium. |
Hendrick, E., Matheus, N., Peixoto, P., Polese, C., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., Elmoualij, B., De Tullio, P., Castronovo, V., & Mottet, D. (05 December 2013). HDAC5 depletion Decreases NDUFB5 Subunit of Mitochondrial Complex- I leading to Glucose-dependent Metabolic Reprogrammation [Poster presentation]. Séminaire des chercheurs Télévie 2014, Bruxelles, Belgium. |
Hendrick, E., Matheus, N., Peixoto, P., Polese, C., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Castronovo, V., & Mottet, D. (13 September 2013). Complexe I mitochondrial dysfunction in HDAC5 depleted cancer cells induces glucose-dependent metabolic reprogrammation [Poster presentation]. Annual Mini symposium 2013, Bruxelles, Belgium. |
Hendrick, E., Matheus, N., Peixoto, P., Polese, C., Blomme, A., Mouithys-Mickalad, A., Serteyn, D., De Tullio, P., Elmoualij, B., Castronovo, V., & Mottet, D. (17 May 2013). Mitochondrial dysfunction in HDAC5-depleted cancer cells induces glucose-dependent metabolic adaptation [Poster presentation]. GIGA-Cancer Day 2013, Liège, Belgium. |
Hendrick, E., Matheus, N., Peixoto, P., Polese, C., Mouithys-Mickalad, A., Serteyn, D., Michiels, C., Castronovo, V., & Mottet, D. (02 February 2013). JNK/ROS signaling pathway is responsible for induction of autophagy in HDAC5 depleted cancer cells [Poster presentation]. Association Belge pour l'étude du cancer A.B.E.C 2013, Gand, Belgium. |
Hendrick, E., Matheus, N., Peixoto, P., Polese, C., Mouithys-Mickalad, A., Serteyn, D., Castronovo, V., & Mottet, D. (29 January 2013). JNK/ROS Signaling Pathway Is Responsible for Induction of Autophagy in HDAC5 depleted Cancer Cells [Paper presentation]. Journée Scientifique des doctorants en sciences Biomédicales et Pharmaceutiques, Mons, Belgium. |
Hendrick, E., Matheus, N., Peixoto, P., Polese, C., Thiry, M., Mouithys-Mickalad, A., Serteyn, D., & Castronovo, V. (28 January 2013). JNK/ROS signaling pathway is responsible for induction of autophagy in HDAC5 depleted cancer cells [Poster presentation]. Giga Day 2013, Liège, Belgium. |
Hendrick, E., Peixoto, P., Matheus, N., Polese, C., Castronovo, V., & Mottet, D. (10 December 2012). Role of HDAC5 depletion induced autophagy on cancer cell death [Poster presentation]. Séminaires des chercheurs Télévie 2013, Liège, Belgium. |
Gengoux, E., LORQUET, S., Hendrick, E., Berndt, S., Noël, A., Foidart, J.-M., Munaut, C., & Pequeux, C. (2011). Basal and induced release of soluble VEGFR-2 by endothelial and lymphatic cells [Poster presentation]. Giga Day, Liège, Belgium. |